Evidence map›Paper›PMID 39758881›Full record

ArticleAntimicrobial stewardship & healthcare epidemiology : ASHE2024

Incidence, healthcare and out-of-pocket costs, and mortality of

Holly Yu, Tamuno Alfred, Jingying Zhou, Jennifer Judy, Margaret A Olsen

Abstract read
In one paragraph

Article in Antimicrobial stewardship & healthcare epidemiology : ASHE, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Holly YuHealth Economics and Outcomes Research, Pfizer Inc, Collegeville, PA, USA.ORCID https://orcid.org/0000-0001-8625-4201
Tamuno AlfredStatistical Research and Data Science Center, Pfizer Inc, New York, NY, USA.
Jingying ZhouStatistical Data Sciences & Analytics, Pfizer Inc, Peapack, NJ, USA.
Jennifer JudyEvidence Generation Platform, Real World Evidence, Pfizer Inc, New York, NY, USA.ORCID https://orcid.org/0000-0002-2246-9745
Margaret A OlsenDepartments of Medicine and Surgery, Washington University School of Medicine, St. Louis, MO, USA.ORCID https://orcid.org/0000-0001-7070-9320

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To estimate incidence and healthcare costs and mortality associated with Design: Retrospective cohort study. Patients: First CDI episodes among commercially insured US patients 18-64 years old were identified from a large claims database. CDI+ patients were propensity score-matched (PSM) 1:1 with CDI- controls using clinically relevant variables including comorbidities. Methods: Annual CDI incidence was calculated by age group and year (2015-2019). Healthcare utilization, costs, and mortality were analyzed by age group, acquisition (healthcare and community), and hospitalization status by calculating CDI-excess costs and mortality as the difference between PSM CDI+ and CDI- individuals. Results: In 50-64- and 18-49-year-olds, respective CDI incidence per 100,000 person-years decreased from 217 and 113 cases in 2015 to 167 and 87 cases in 2019. Most cases (76.5%-86.9%) were community-associated. The costs and mortality analyses included 6,332 matched CDI+/- 50-64-year-olds and 6,667 CDI+/- 18-49-year-olds. Among 50-64-year-olds, mean 2-month healthcare and patients' out-of-pocket costs were $11,634 and $573 higher, respectively, in the CDI+ versus CDI- group. Among 18-49-year-olds, 2-month costs were $7,826 and $642 higher. Healthcare costs were higher for healthcare- versus community-associated CDI. At the 12-month follow-up, mortality was significantly higher in the CDI+ versus CDI- groups for both 50-64-year-olds (4.2% vs 2.0%; Conclusions: Prevention of CDI among adults 18-64 years old may significantly reduce costs and mortality.

Identifiers

PMID39758881
PMCPMC11696600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.